Vimarsana
Biggest News Aggregation in the World

Page 33 - Colitis Foundation News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Colitis Foundation. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Colitis Foundation Today - Breaking & Trending Today

Raffle helps Crohn's and colitis research, offers Gloria Estefan dinner as prize - Vimarsana News

Raffle helps Crohn's and colitis research, offers Gloria Estefan dinner as prize

Crohn’s & Colitis Foundation holds Night of Hope fundraiser with opportunity to win a private dinner for 8 with Emilio and Gloria Estefan.

Edelstein to be honored by Crohn's & Colitis Foundation | Local News - Vimarsana News

Edelstein to be honored by Crohn's & Colitis Foundation | Local News

When Robert Edelstein was 8 years old, he was diagnosed with Crohn’s disease. Now, 57 years later at age 65, he will be honored by the Crohn’s & Colitis Foundation

Crohn's disease and Colitis: Advocates strive to raise awareness, break for two 'invisible illnesses' - Vimarsana News

Crohn's disease and Colitis: Advocates strive to raise awareness, break for two 'invisible illnesses'

Foundation will host its annual gala later this month to raise awareness of the two inflammatory bowel diseases, and funds in search of a cure

The Inner Circle Acknowledges, Dr. Susan T. Wolgamott, DNP, FNP-C, CTN-B as a Top Pinnacle Healthcare Professional for her contributions to the field of Gastroenterology - Vimarsana News

The Inner Circle Acknowledges, Dr. Susan T. Wolgamott, DNP, FNP-C, CTN-B as a Top Pinnacle Healthcare Professional for her contributions to the field of Gastroenterology

/PRNewswire/ -- Prominently featured in The Inner Circle, Dr. Susan T. Wolgamott, DNP, FNP-C, CTN-B is acknowledged as a Top Pinnacle Healthcare Professional...

AbbVie's SKYRIZI® (risankizumab) Versus STELARA® (ustekinumab) Head-to-Head Study in Crohn's Disease Meets All Primary and Secondary Endpoints - Vimarsana News

AbbVie's SKYRIZI® (risankizumab) Versus STELARA® (ustekinumab) Head-to-Head Study in Crohn's Disease Meets All Primary and Secondary Endpoints

SEQUENCE, a Phase 3 head-to-head study, compared risankizumab to ustekinumab for the treatment of adult patients with moderately to severely active Crohn's...